Health Care Services

Cross Country Healthcare

Cross Country Healthcare released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 241.06 M (forecast USD 236.84 M), actual EPS USD -0.14 (forecast USD -0.048)

Cross Country Healthcare to release FY2026 Q1 earnings on May 7 After-Market EST, forecast revenue USD 236.84 M, EPS USD -0.048

Cross Country Healthcare Reports 2025 Fiscal Year Financial Performance

Cross Country Healthcare released FY2025 Q4 earnings on March 4 After-Market (EST), actual revenue USD 236.76 M (forecast USD 254.3 M), actual EPS USD -2.5656 (forecast USD -0.0125)

Cross Country Healthcare released FY2025 earnings on March 4 After-Market EST, actual revenue USD 1.054 B (forecast USD 1.072 B), actual EPS USD -2.93 (forecast USD -0.3814)

Cross Country Healthcare to Release FY2025 Q4 Earnings on March 4 After-Market EST, Forecast Revenue USD 254.3 M, EPS USD -0.002

Barclay Maintains Hold Rating on Cross Country Healthcare Stock

Cross Country Healthcare released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 250.05 M (forecast USD 270.72 M), actual EPS USD -0.15 (forecast USD 0.0275)

Cross Country Healthcare released FY2025 9 Months earnings on November 12 EST, actual revenue USD 567.48 M, actual EPS USD -0.2249

Cross Country Healthcare released FY2025 Q2 earnings on August 6 (EST), actual revenue USD 274.07 M (forecast USD 292.19 M), actual EPS USD -0.2049 (forecast USD 0.045)

Cross Country Healthcare released FY2025 Semi-Annual Earnings on August 6, 2025 (EST) with actual revenue of USD 567.48 M and EPS of USD -0.2207

Ohio Public Employees Retirement System Significantly Reduces Holdings in Cross Country Healthcare

StockNews.com provides Cross Country Healthcare with a 'Hold' rating

Tudor Investment Corp ET AL Increased Holdings of Cross Country Healthcare in Q4

Cross Country Healthcare released FY2025 Q1 earnings on May 7 (EST), actual revenue USD 293.41 M (forecast USD 314.82 M), actual EPS USD -0.02 (forecast USD 0.0663)

Cross Country Healthcare Posts $500,000 Net Loss in Q1 2025

Legal & General Group Plc reduced its holdings in Cross Country Healthcare Inc. in Q4

Russell Investments Reduces Holdings in Cross Country Healthcare

Cross Country Healthcare (CCRN) Faces Arbitrage Opportunity in Acquisition of Aya Healthcare

Cross Country Healthcare released FY2024 annual earnings on March 5 (EST), actual revenue $1.344 B (forecast $1.34 B), actual EPS -$0.44 (forecast -$0.2075)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

CCRN

Cross Country Healthcare, Inc. (Nasdaq: CCRN) has announced a 36-month exclusive partnership to integrate the Optimé workforce strategy solution into its Intellify® platform. This collaboration aims to enhance staffing precision and operational efficiency for health systems by providing advanced forecasting and optimization capabilities. The Optimé solution will help align workforce supply with patient demand, reduce labor costs, and improve decision-making processes. This partnership marks a significant step in Cross Country's evolution towards becoming a technology-enabled workforce partner in the healthcare sector.

StockTitan

Cross Country Expands AI-Powered Workforce Intelligence for Health Systems Through Exclusive Optimé Solution | CCRN Stock News

Truist Financial has raised its price target for Cross Country Healthcare (NASDAQ:CCRN) from $10.00 to $13.25, maintaining a "hold" rating. This new target suggests a potential upside of 0.88% from the stock's previous close. Other analysts have varied opinions, with Weiss Ratings issuing a "sell" and Citigroup downgrading to "market perform." Currently, CCRN trades at $13.14, with a market cap of $422.95 million and a consensus price target of $12.72.

Market Beat

SPDR S&P Health

iShares US Healthcare Providers

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

Truist Financial

Citigroup

Citizens Financial

BNP Paribas

Meta Platforms

CITIGROUP INC 6.250 NON CUM SER II PFD WI

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

Cross Country Healthcare (NASDAQ:CCRN) Price Target Raised to $13.25 at Truist Financial

Cross Country Healthcare (NASDAQ:CCRN) reported quarterly earnings of ($0.03) EPS, exceeding expectations of ($0.05) by $0.02. The company generated revenue of $241.06 million, surpassing estimates of $236.84 million. Despite a negative net margin of 9.84% and a return on equity of -0.71%, the stock saw a slight increase to $13.18. The company is set to be acquired by Knox Lane for $13.25 per share, influencing market sentiment. Analysts have mixed ratings, with some downgrading the stock while others maintain a hold rating.

AllianceBernstein

Goldman Sachs

Charles Schwab

Dan IVES Wedbush AI Revolution ETF

GS Hldg R

SCHWAB(CHARLES)CORP 5.95% DEP SHS REP 1/40 NON CUM PERP PF D

SCHWAB(CHARLES)CORP 4.450% DEP SHS REP 1/40TH N-CUM PFD SERJ

Cross Country Healthcare (NASDAQ:CCRN) Releases Earnings Results, Beats Expectations By $0.02 EPS

Earnings Watch

Cross Country Healthcare | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 241.06 M

ATRA

OSRH

In Thursday's trading session, several health care stocks experienced significant movements. Agilon Health (AGL) surged 115.7% to $60.08 following its Q1 earnings report. Atara Biotherapeutics (ATRA) rose 92.23% to $9.9, while Cross Country Healthcare (CCRN) increased by 29.52% to $13.1. Other gainers included SenesTech (SNES) up 25.85% and OSR Holdings (OSRH) up 20.66%. Conversely, LosersenGene Therapeutics (ENGN) plummeted 79.7% to $1.79, and Entrada Therapeutics (TRDA) fell 58.86% to $6.59. Accuray (ARAY) and Pharming (PHAR) also saw declines of 28.73% and 27.6%, respectively.

benzinga_article

agilon health

Atara Biotherap

Senestech

Ernexa Therapeutics

enGene Therapeutics

Entrada Therapeutics

Accuray

Pharming Group NV

Apimeds Pharmaceuticals US

Aspire Biopharma

OSR HOLDINGS INC C/WTS 09/02/2028 (TO PUR COM)

ENGENE THERAPEUTICS INC C/WTS 31/10/2028 (TO PUR COM)

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM)

12 Health Care Stocks Moving In Thursday's Intraday Session

Knox Lane is set to acquire Cross Country Healthcare, Inc. for $437 million in an all-cash deal, with shares surging over 28% following the announcement. The acquisition price is $13.25 per share, and the transaction is expected to close in Q3 2026, making Cross Country a privately held company. BofA Securities is the financial advisor for the deal. CCRN's stock closed at $10.11, down 5.25%, but rose to $13.03 in pre-market trading.

nasdaq

Nasdaq

Knox Lane To Acquire Cross Country Healthcare In $437 Mln All-Cash Deal; Stock Up